- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
S&P Global upgraded Biocon Biologics' credit outlook to 'Positive' on accelerated debt reduction plans. Biocon will acquire minority stakes via equity swaps and a ~4,500 Cr equity issuance. This move is projected to slash adjusted debt from ~24,800 Cr to ~12,000 Cr by March 2026.